Unconfigured Ad

Collapse
X
 
  • Filter
  • Time
  • Show
Clear All
new posts
  • RockChalkJayhawk
    Senior Member
    • Mar 2009
    • 192

    Abberant junctions by tophat

    I have tried to align my paired end RNA-Seq reads to the genome using Tophat. I ran a sample dataset from the SRA (SR018268_1 and _2) and the data looked fine. However, when I run my datasets, I get a lot of spurrious junctions. In the attached example, I show the junctions and coverage for one sample. All the exons map beautifully and have coverage > 200X, but the junctions between exons were not determined for almost all of these exons are not joined and the majority of "junctions" (>80%) in the dataset are intergenic (or intragenic) even with low coverage. For exampl, the far left junction is supported by 92 reads, the middle by 83, and the right by 2.

    I have tried to manipulate the alignment parameters such as -r set to either 165 or 41. These correspond to 230 bp DNA identified from the bioanalyzer minus the inner distance alone (230-35-35=165) or including the primer sequences (230-35-35-119=41). This didn't really change things much.

    So my questions are:
    1) Why aren't these junctions being called by tophat?
    2) Why would the junction on the right show up?
    3) How do I get past this?
    Attached Files
  • Cole Trapnell
    Senior Member
    • Nov 2008
    • 213

    #2
    How long are these reads?

    Comment

    • RockChalkJayhawk
      Senior Member
      • Mar 2009
      • 192

      #3
      these are 2 x 35 bp reads. I also don't know if this matters, but my mapping qualities from the SAM files are:
      632465 0
      368741 1
      38907221 255
      1170126 3


      Does this matter?
      Last edited by RockChalkJayhawk; 05-05-2010, 01:47 PM. Reason: Update

      Comment

      • RockChalkJayhawk
        Senior Member
        • Mar 2009
        • 192

        #4
        Also, when I was trying to figure all this out, I made a fastq file that was only 100K long to troubleshoot and I ran into another problem. There are instances where junctions (true ones) appear only when the small dataset is used and not when the full dataset is used. Otherwise, they are exactly the same.

        For instance, this figure shows no junctions when this gene is sequenced 33,333 times, but by subselecting and mapping with only 45x coverage, most of the exons are joined together.

        Where did they go in the full analysis?

        I am using the following code:
        Code:
        tophat -r 41 -p 6 --solexa1.3-quals hg19 sequence_1 sequence_2
        Attached Files

        Comment

        Latest Articles

        Collapse

        • SEQadmin2
          Proteomic Platforms: How to Choose the Right Analytical Strategy to Improve Detection and Clinical Applications
          by SEQadmin2


          Proteomics platforms are evolving rapidly, with advances in mass spectrometry and affinity-based approaches expanding what researchers can detect and at what scale. As the field moves toward deeper proteome coverage and clinical applications, scientists face an increasingly complex landscape of tools. This article will explore how researchers are navigating these choices to find the right platform for their work.

          The systematic characterization of the human proteome has
          ...
          Yesterday, 11:48 AM
        • SEQadmin2
          Advanced Sequencing Platforms Tackle Neuroscience’s Toughest Genomics Problems
          by SEQadmin2



          Genomics studies in neuroscience face a special challenge due to the brain’s complexity and scarcity of samples. Mapping changes in cell type and state using conventional next-generation sequencing methods remains challenging. Advances in technologies like single-cell sequencing, spatial transcriptomics, and long-read sequencing have opened the door to deeper studies of the brain and diseases like Alzheimer’s, amyotrophic lateral sclerosis (ALS), and schizophrenia.
          ...
          07-09-2026, 11:10 AM
        • SEQadmin2
          Cancer Drug Resistance: The Lingering Barrier to Rising Survival
          by SEQadmin2



          Cancer survival rates have significantly increased in the last few decades in the United States, reaching a combined 70% 5-year survival rate by 2021. Behind this number, there are years of research to find new therapies, drug targets, and early detection methods. But there is one core challenge that keeps slowing down these advances, and it’s about drug resistance.

          There is no single reason why many patients don’t respond to treatment as expected. Cancer is...
          07-08-2026, 05:17 AM

        ad_right_rmr

        Collapse

        News

        Collapse

        Topics Statistics Last Post
        Started by SEQadmin2, Yesterday, 11:10 AM
        0 responses
        9 views
        0 reactions
        Last Post SEQadmin2  
        Started by SEQadmin2, 07-13-2026, 10:26 AM
        0 responses
        30 views
        0 reactions
        Last Post SEQadmin2  
        Started by SEQadmin2, 07-09-2026, 10:04 AM
        0 responses
        40 views
        0 reactions
        Last Post SEQadmin2  
        Started by SEQadmin2, 07-08-2026, 10:08 AM
        0 responses
        25 views
        0 reactions
        Last Post SEQadmin2  
        Working...